Rocuronium Bromide Injection, Solution
Product Images NDC 71872-7207

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Rocuronium Bromide (NDC 71872-7207). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medical Purchasing Solutions, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71872-7207-1.pdp (71872 7207 1)

Text panel for Rocuronium Bromide Injection, USP 10 mg/mL in a 5 mL multiple dose vial. The panel includes warnings about its paralytic effects and respiratory risks, storage instructions requiring refrigeration without freezing, and composition details. It also lists distributors Hospira, Inc. and Medical Purchasing Solutions, LLC, with manufacturing information and website details.*

FDA Label Image

Structural Formula Rocuronium Bromide (Rocuronium 01)

Chemical structure of Rocuronium Bromide, depicting its molecular arrangement including the steroid backbone, quaternary ammonium group, ester moiety, and bromide ion, consistent with the active ingredient in the injectable solution form.*

FDA Label Image

Figure 1: Time To 80% Or Greater Block Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium 02)

Box plot chart titled 'Time to 80% or greater Block vs. Initial Dose of Rocuronium Bromide by Age Group,' showing median, 25th and 75th percentiles, and individual values. The x-axis displays initial dose in mg/kg for age groups 18-64 years, 65 years and older, and 1-12 years. The y-axis represents time in minutes to reach 80% or more block.*

FDA Label Image

Figure 2: Duration Of Clinical Effect Vs. Initial Dose Of Rocuronium Bromide By Age Group (median, 25th And 75th Percentile, And Individual Values) (Rocuronium 03)

A box plot chart titled 'Duration of Clinical Effect vs. Initial Dose of Rocuronium Bromide by Age Group.' The y-axis represents duration in minutes (0 to 160), and the x-axis shows initial Rocuronium Bromide dose in mg/kg for four age categories: 18-64 years, 65 years and older, 3 months to 1 year, and 1 to 12 years. The chart displays median, 25th and 75th percentiles, and individual values.*

FDA Label Image

Figure 3: Duration Of Clinical Effect Vs. Number Of Rocuronium Bromide Maintenance Doses, By Dose (Rocuronium 04)

A line graph titled "Duration of Clinical Effect vs. Number of Rocuronium Bromide Maintenance Doses, by Dose" showing minutes on the y-axis (0 to 30) and dose number on the x-axis (0 to 6). Two lines represent doses of 0.10 mg/kg (lower line, N=29) and 0.15 mg/kg (upper line, N=13), depicting the duration of clinical effect increasing with dose number and then plateauing.*

FDA Label Image

Hospira Logo (Rocuronium 05)

FDA Label Image

Principal Display Panel (5 mL Vial Label)

Rocuronium Bromide Injection 10 mg/mL (50 mg/5 mL) multiple dose vial label. The label includes a red warning stating it is a paralyzing agent causing respiratory arrest and intended for intravenous use only. It is distributed by Hospira, Inc., Lake Forest, IL USA. The label provides dosage, storage instructions, and identifies the product as prescription only.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.